Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19N3O4S |
| Molecular Weight | 349.405 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN4C=CN=C4C3)=C(N2C1=O)C(O)=O
InChI
InChIKey=SYFIHQJVKJGGGB-SXLYUPOASA-N
InChI=1S/C16H19N3O4S/c1-7-12-11(8(2)20)15(21)19(12)13(16(22)23)14(7)24-9-5-10-17-3-4-18(10)6-9/h3-4,7-9,11-12,20H,5-6H2,1-2H3,(H,22,23)/t7-,8-,9+,11-,12-/m1/s1
| Molecular Formula | C16H19N3O4S |
| Molecular Weight | 349.405 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:08:52 GMT 2025
by
admin
on
Mon Mar 31 23:08:52 GMT 2025
|
| Record UNII |
VL8A7ME6X8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
VL8A7ME6X8
Created by
admin on Mon Mar 31 23:08:52 GMT 2025 , Edited by admin on Mon Mar 31 23:08:52 GMT 2025
|
PRIMARY | |||
|
DTXSID501338049
Created by
admin on Mon Mar 31 23:08:52 GMT 2025 , Edited by admin on Mon Mar 31 23:08:52 GMT 2025
|
PRIMARY | |||
|
9819755
Created by
admin on Mon Mar 31 23:08:52 GMT 2025 , Edited by admin on Mon Mar 31 23:08:52 GMT 2025
|
PRIMARY | |||
|
DU 6681
Created by
admin on Mon Mar 31 23:08:52 GMT 2025 , Edited by admin on Mon Mar 31 23:08:52 GMT 2025
|
PRIMARY | |||
|
129951-17-3
Created by
admin on Mon Mar 31 23:08:52 GMT 2025 , Edited by admin on Mon Mar 31 23:08:52 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
DZ-2640 is the ester-type oral carbapenem prodrug of an active parent compound, DU-6681. The pharmacokinetics and safety of DU-6681 were investigated in six studies after oral administration of a single dose of DZ-2640 to healthy male Japanese volunteers at doses of 25, 50, 100, 200, and 400 mg (as the equivalents of DU-6681) in the fasted state.
|